Jump to content

PubMed RSS Feed - -Tranexamic acid microinjections : a novel treatment option for erythematotelangiectatic rosacea


Recommended Posts

J Cosmet Dermatol. 2021 May 10. doi: 10.1111/jocd.14209. Online ahead of print.


BACKGROUND: Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.

AIMS: to evaluate the efficacy and safety of intradermal microinjections of TXA for ETR.

PATIENTS/METHODS: This was a retrospective study enrolling patients, treated with TXA intradermal microinjections for ETR, from January 2019 to February 2020. Response to treatment was assessed based on subjective symptoms, clinical photographs and the Investigator Global Assessment of Rosacea Severity Score (IGA-RSS).

RESULTS: Six patients were included. The mean number of monthly intradermal TXA microinjections was 5.1±1.3. The mean decrease of IGA-RSS was 2.4±0.5. Local side effects, mainly transient erythema and swelling, were noticed in three cases. No systemic effects were noted. Clinical improvement, in respondent patients, lasted after 3 months of follow-up.

CONCLUSION: Intradermal TXA microinjections is a safe and effective treatment option for ETR. The optimal number of monthly sessions has yet to be determined.

PMID:33973361 | DOI:10.1111/jocd.14209

{url} = URL to article

More information on TXA 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use